FDA approved avelumab 6/30/2020

EMD Serono
  • FLASCO
  • July 2, 2020

Food and Drug Administration approved avelumab (BAVENCIO, EMD Serono, Inc.) for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. More Information. June 30, 2020

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment

Hematology/Oncology (Cancer) Approvals & Safety Notifications

https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications

© 2020 FLASCO | Premium Website Design by The HDG

FLASCO